



Figure S2

A

Western-blot validation of siRNAs




B IF validation of siRNAs



C

qPCR validation of siRNAs



D

Full membrane images of the Htt blots




Figure S2 - Supplementary to Figure 2: Validation of siRNAs

(A) Representative western-blot showing the knock-down of target by Mapk11/MAPK11 siRNAs in both mouse (STHdh) and human (fibroblasts) cells, and HIPK3 siRNAs in human cells (fibroblasts). Due to many non-specific bands around 80 kD and low antibody affinity, we failed to detect mouse endogenous Hipk3 protein-specific western-blot signals in STHdh cells.

(B) Immunofluorescence (IF) experiments confirming the expression and knock-down of Hipk3 proteins in the STHdh cells. Scale bar: 20 μ m. The anti-Hipk3 antibody from GeneTex (#GTX108369) was used as the primary antibody, and the same antibody was used for human putamen slices (Figure S3E). This antibody fails to give signals in western-blot experiments.

(C) qPCR results showing the knock-down of target by the kinase siRNAs used in this study. Different siRNAs were used for human and mouse targets and validated in mouse (left three panels) and human cells (right three panels), respectively. Expression is normalized to the Scramble siRNA transfected control sample. Data are plotted as mean and s.e.m.

(D) Full-membrane blots of the Htt western-blot in Fig. 2A showing that the reduction of full length Htt is not due to increase of cleavage products.